Molecular hybridization: A useful tool in the design of new drug prototypes

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Federal do Rio de Janeiro (UFRJ)
dc.date.accessioned2014-05-27T11:22:31Z
dc.date.available2014-05-27T11:22:31Z
dc.date.created2014-05-27T11:22:31Z
dc.date.issued2007-07-01
dc.identifierCurrent Medicinal Chemistry, v. 14, n. 17, p. 1829-1852, 2007.
dc.identifier0929-8673
dc.identifierhttp://hdl.handle.net/11449/69763
dc.identifier10.2174/092986707781058805
dc.identifierWOS:000247774200003
dc.identifier2-s2.0-34547484265
dc.identifier4484083685251673
dc.description.abstractMolecular hybridization is a new concept in drug design and development based on the combination of pharmacophoric moieties of different bioactive substances to produce a new hyrid compound with improved affinity and efficacy, when compared to the parent drugs. Additionally, this strategy can results in compounds presenting modified selectivity profile, different and/or dual modes of action and reduced undesired side effects. So, in this described several example of different strategies for drug design, discovery and pharmacomodulation focused on new innovative hybrid compounds presenting analgesic, anti-inflammatory, platelet anti-aggregating, anti-infections, anticancer, cardio- and neuroactive properties.
dc.languageeng
dc.relationCurrent Medicinal Chemistry
dc.relation3.469
dc.relation1,015
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectDrug design
dc.subjectHybrid compounds
dc.subjectMolecular hybridization
dc.subjectPharmacophoric group combination
dc.subject1,2,3,11a tetrahydro 8 hydroxy 7 methoxy 5h pyrrolo[2,1 c][1,4]benzodiazepin 5 one
dc.subject1h 1,2,4 oxadiazolo[4,3 a]quinoxalin 1 one
dc.subjectacetylsalicylic acid
dc.subjectagmatine
dc.subjectalpha tocopherol
dc.subjectanalgesic agent
dc.subjectanthramycin
dc.subjectantiinfective agent
dc.subjectantiinflammatory agent
dc.subjectantineoplastic agent
dc.subjectantithrombocytic agent
dc.subjectbenzocaine
dc.subjectciprofloxacin
dc.subjectdipyrone
dc.subjectdistamycin A
dc.subjectdolastatin
dc.subjectgeldanamycin
dc.subjectlidocaine
dc.subjectlosartan
dc.subjectmetoclopramide
dc.subjectmitiglinide
dc.subjectnateglinide
dc.subjectnorfloxacin
dc.subjectprocainamide
dc.subjectpropranolol
dc.subjectsparfloxacin
dc.subjecttaltobulin
dc.subjectunindexed drug
dc.subjecturamustine
dc.subjectzatebradine
dc.subjectanalgesia
dc.subjectantiarrhythmic activity
dc.subjectantiinflammatory activity
dc.subjectantimicrobial activity
dc.subjectantineoplastic activity
dc.subjectantioxidant activity
dc.subjectbinding affinity
dc.subjectblood pressure regulation
dc.subjectdrug design
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectdrug research
dc.subjectdrug selectivity
dc.subjectdrug structure
dc.subjecthuman
dc.subjectmolecular hybridization
dc.subjectnonhuman
dc.subjectpharmacophore
dc.subjectreview
dc.subjectsmooth muscle relaxation
dc.subjectstructure activity relation
dc.subjectthrombocyte aggregation inhibition
dc.subjectvasodilatation
dc.subjectAnalgesics
dc.subjectAnimals
dc.subjectAnti-Infective Agents
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectAntineoplastic Agents
dc.subjectCardiovascular Agents
dc.subjectDrug Design
dc.subjectFibrinolytic Agents
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectLigands
dc.titleMolecular hybridization: A useful tool in the design of new drug prototypes
dc.typeOtros


Este ítem pertenece a la siguiente institución